Aurinia Pharmaceuticals is a dedicated biopharmaceutical company focused on transforming the treatment landscape for autoimmune diseases with unmet medical needs. With a mission to change the trajectory of these diseases, Aurinia is committed to providing high-quality, safe, and effective medical treatments, including their approved therapy, LUPKYNIS™, for lupus nephritis. The company emphasizes a culture of collaboration, resilience, and accountability, ensuring that every team member contributes to the goal of enabling patients to live their fullest lives. Aurinia's strategic approach leverages the expertise of its team in drug development and commercialization, fostering an environment where innovation and quality are paramount.